MLYS

Business Context and Reporting Period

Company: Mineralys Therapeutics, Inc. (MLYS)
Reporting Period: Quarter ended March 31, 2025 (Q1 2025)
Business Overview: Mineralys is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor, for cardiorenal conditions including hypertension, chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The company has no approved products and has not generated revenue.

Key Financial Metrics

Note: Cash, cash equivalents, and investments total $343.0 million as of March 31, 2025, comprising $165.0 million in cash/cash equivalents and $178.0 million in investments.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by $10.7 million (34%) to $42.2 million, driven primarily by higher operating expenses.
• R&D Expense Growth: R&D expenses rose by $7.1 million, attributed to a $4.8 million increase in preclinical and clinical costs and a $2.8 million increase in compensation and stock-based compensation.
• G&A Expense Growth: G&A expenses increased by $2.0 million due to higher compensation costs and professional fees.
• Capital Raise: In March 2025, the company completed a public offering of 14.9 million shares at $13.50 per share, generating net proceeds of approximately $188.7 million. This significantly bolstered liquidity compared to the prior year's private placement of $116.1 million.
• Investment Activity: Net cash used in investing activities increased to $92.9 million (from $56.0 million) due to the timing and volume of marketable securities purchases and maturities.

Guidance, Outlook, and Risks

Clinical Progress and Outlook

• Pivotal Trial Success: In March 2025, the company announced that its pivotal trials (Launch-HTN and Advance-HTN) for uncontrolled/resistant hypertension met primary efficacy endpoints with statistical significance.
• Regulatory Path: Management anticipates a pre-New Drug Application (NDA) meeting with the FDA in Q4 2025.
• Ongoing Trials: Topline data for the Explore-CKD trial (hypertension with CKD) is expected in Q2 2025. Enrollment is ongoing for the Explore-OSA trial (hypertension with obstructive sleep apnea).
• Liquidity: Management believes current cash, cash equivalents, and investments ($343.0 million) are sufficient to fund operations for at least 12 months from the filing date.

Risks and Contingencies

• Capital Requirements: The company expects to incur substantial losses in the foreseeable future and will require additional funding for future development and commercialization.
• License Obligations: Under the license agreement with Mitsubishi Tanabe, the company has potential commercial milestone obligations of up to $155.0 million and tiered royalties (mid-single digits to 10%) on net sales.
• Market Risks: Risks include inflation, trade policy changes (tariffs), and potential difficulties in securing future financing on favorable terms.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $343.0 million cash position against the projected burn rate for the upcoming 12 months, considering the high cost of late-stage clinical trials.
• Regulatory Timeline: Confirm the timing of the anticipated Q4 2025 pre-NDA meeting with the FDA and any potential delays.
• Dilution Risk: Monitor future equity offerings or debt financings required to fund operations beyond the 12-month horizon, which may dilute existing shareholders.
• Clinical Data Validation: Review the full data release for the Launch-HTN and Advance-HTN trials to assess the durability of the blood pressure reduction and safety profile (specifically hyperkalemia rates).
• License Milestones: Track progress toward commercial milestones that would trigger payments to Mitsubishi Tanabe, totaling up to $165.0 million in potential future obligations.